Latham & Watkins Advises on Fulgent Genetics’ Acquisition of Bako Diagnostics and StrataDX

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent), a technology-based company with a well-established laboratory services business and a therapeutic development business, has announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a premier pathology laboratory headquartered in Alpharetta, Georgia and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, Massachusetts. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately US$55.5 million, subject to adjustments, to be paid from cash on hand. The acquisition is expected to close during the first half of 2026, subject to satisfying customary closing conditions, including regulatory approvals.

Latham & Watkins LLP represented Consonance Capital Partners, Bako Diagnostics, and StrataDx in the transaction with a corporate deal team led by New York partners David Allinson and Edmond Parhami, with associates Josh Barkow and Samyung Han. Advice was also provided on tax matters by New York partner Matthew Dewitz, with associate Jack Santoro; on executive compensation, employment, and benefits matters by New York partners Bradd Williamson and Max Raskin, with associates Anne Josephine Bracaglia and Seokwon Lee; on labor matters by Chicago partner Nineveh Alkhas, with associate Jocelyn Wexler; on healthcare matters by Washington, D.C. partner Jason Caron, with associates Yanyan Zhou and Danny Machado; on intellectual property matters by associates Deborah Hinck, Susana Santos, Zachary Shufro, and Victoria Allen; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with Houston associate Chad Leiper; and on insurance matters by Los Angeles partner Harrison White.